Macquarie Group Ltd. trimmed its position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 69,313 shares of the biopharmaceutical company’s stock after selling 3,089 shares during the period. Macquarie Group Ltd. owned 0.15% of Sucampo Pharmaceuticals worth $1,244,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Trexquant Investment LP bought a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter worth $122,000. FDx Advisors Inc. bought a new stake in shares of Sucampo Pharmaceuticals during the 4th quarter worth $180,000. UBS Asset Management Americas Inc. bought a new stake in shares of Sucampo Pharmaceuticals during the 4th quarter worth $192,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Sucampo Pharmaceuticals by 4.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 790 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board bought a new stake in shares of Sucampo Pharmaceuticals during the 4th quarter worth $218,000. 67.09% of the stock is owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals stock opened at $18.00 on Friday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals, Inc. has a twelve month low of $9.30 and a twelve month high of $18.75.
A number of analysts have recently issued reports on SCMP shares. Instinet started coverage on shares of Sucampo Pharmaceuticals in a report on Tuesday, December 19th. They set a “buy” rating and a $43.00 price objective for the company. Nomura started coverage on shares of Sucampo Pharmaceuticals in a report on Monday, December 18th. They set a “buy” rating and a $43.00 price objective for the company. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Thursday, February 1st. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Finally, Maxim Group downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Eight analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $20.73.
ILLEGAL ACTIVITY NOTICE: “Macquarie Group Ltd. Has $1.24 Million Holdings in Sucampo Pharmaceuticals, Inc. (SCMP)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/macquarie-group-ltd-has-1-24-million-holdings-in-sucampo-pharmaceuticals-inc-scmp.html.
Sucampo Pharmaceuticals Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.